ProMIS Neurosciences (ProMIS Neurosciences) Operating Cash Flow per Share : $-1.17 (TTM As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences Operating Cash Flow per Share?

ProMIS Neurosciences's operating cash flow per share for the three months ended in Mar. 2024 was $-0.53. ProMIS Neurosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.17.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -7.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -0.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for ProMIS Neurosciences's Operating Cash Flow per Share or its related term are showing as below:

PMN' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -36.2 Med: 6.4 Max: 38.7
Current: -7.1

During the past 13 years, ProMIS Neurosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 38.70% per year. The lowest was -36.20% per year. And the median was 6.40% per year.

PMN's 3-Year OCF Growth Rate is ranked worse than
63.53% of 1234 companies
in the Biotechnology industry
Industry Median: 3.45 vs PMN: -7.10

ProMIS Neurosciences Operating Cash Flow per Share Historical Data

The historical data trend for ProMIS Neurosciences's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences Operating Cash Flow per Share Chart

ProMIS Neurosciences Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-1.08

-0.72

-1.61

-2.27

-0.88

ProMIS Neurosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.30	-0.25	-0.19	-0.20	-0.53

Competitive Comparison of ProMIS Neurosciences's Operating Cash Flow per Share

For the Biotechnology subindustry, ProMIS Neurosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProMIS Neurosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's Price-to-Operating-Cash-Flow falls into.

ProMIS Neurosciences Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

ProMIS Neurosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-10.844	/	12.293
	=	-0.88

ProMIS Neurosciences's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-10.291	/	19.534
	=	-0.53

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.17

ProMIS Neurosciences Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ProMIS Neurosciences (ProMIS Neurosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

23J0:Germany

Address

1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2

Website

https://www.promisneurosciences.com

ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It operates in Canada.

Executives

Larry Douglas Altstiel	officer: Chief Medical Officer	C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken	officer: Chief Financial Officer	DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar	10 percent owner	33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel	director, officer: Chief Executive Officer	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury	officer: Principal Accounting Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant	officer: Chief Operating Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Neil Cashman	director, officer: Chief Scientific Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan	officer: Chief Development Officer	PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams	director, officer: Chairman and CEO	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory	director	830 WINTER STREET, WALTHAM MA 02451
Neil K Warma	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman	director	4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Madge K. Shafmaster	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2